West Pharmaceutical Services (WST) Interest & Investment Income (2009 - 2026)

West Pharmaceutical Services (WST) has reported Interest & Investment Income for 18 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• Quarterly Interest & Investment Income rose 5.56% year-over-year to $3.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.7 million (up 9.36% YoY) and the FY2025 annual result came in at $17.5 million, down 10.71% from the prior year.
• Interest & Investment Income declined to $3.8 million in Q2 2026 per WST's latest filing, from $5.1 million in the prior quarter.
• Over the last five years, Interest & Investment Income for WST reached as high as $9.4 million in Q4 2023 and fell as low as $300000.0 in Q1 2022.
• A 5-year average of $4.4 million and a median of $4.6 million in 2024 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2023 — Interest & Investment Income surged 1500.0% — and 2024, when it sank 48.94%.
• Year by year, Interest & Investment Income stood at $2.9 million in 2022, then soared by 224.14% to $9.4 million in 2023, then plunged by 48.94% to $4.8 million in 2024, then increased by 6.25% to $5.1 million in 2025, then dropped by 25.49% to $3.8 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $3.8 million, $5.1 million, and $5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.